Influenza A/H1N1 Vaccine in Patients Treated by Kidney Transplant or Dialysis: A Cohort Study

Nilufer Broeders, Anneleen Hombrouck, Anne Lemy, Karl Martin Wissing, Judith Racape, Karine Gastaldello, Annick Massart, Steven Van Gucht, Laura Weichselbaum, Aurelie De Mul, Bernard Brochier, Isabelle Thomas, Daniel Abramowicz

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background and objectives In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There are few data concerning the immunogenicity or the security of the adjuvanted-A/H1N1 vaccine in transplanted and hemodialyzed patients.

Design, setting, participants, & measurements Sera from 21 controls, 53 hemodialyzed (HD) patients, and 111 renal transplant recipients (RT) were sampled before (T0) and 1 month after (T1) a single dose of Pandemrix (R) vaccine (GSK Biologicals, AS03-adjuvanted). We measured the neutralizing antibodies against A/H1N1/2009, the geometric mean (GM) titers, the GM titer ratios (T1/T0) with 95% confidence intervals, and the seroconversion rate (responders: >= 4-fold increase in titer). The HLA and MICA immunization was determined by Luminex technology.

Results The GM titer ratio was 38 (19 to 78), 9 (5 to 16), and 5 (3 to 6) for controls, HD patients, and RI patients, respectively (P <0.001). The proportion of responders was 90%, 57%, and 44%, respectively (P <0.001). In RT patients, the prevalence of histocompatibility leukocyte antigen (HLA) class I, histocompatibility leukocyte antigen class 11, and MHC class I-related chain A immunization, was, respectively, 15%, 14%, and 14% before and 14%, 14%, and 11% after vaccination (P = 1, 1, and 0.39).

Conclusions The influenza A/H1N1-adjuvanted vaccine is of limited efficacy but is safe in renal disease populations. The humoral response is lower in transplanted versus hemodialyzed patients. Further studies are needed to improve the efficacy of vaccination in those populations. Clin J Am Soc Nephrol 6: 2573-2578, 2011. doi: 10.2215/CJN.04670511
Original languageEnglish
Pages (from-to)2573-2578
Number of pages6
JournalClinical Journal of the American Society of Nephrology
Volume6
Issue numberNOV
Publication statusPublished - 2011

Keywords

  • A H1N1 vaccine
  • MF59-adjuvanted vaccine
  • chronic rejection
  • follow-up
  • recipients
  • virus
  • antibodies
  • immunogenicitiy
  • trial
  • HLA

Fingerprint

Dive into the research topics of 'Influenza A/H1N1 Vaccine in Patients Treated by Kidney Transplant or Dialysis: A Cohort Study'. Together they form a unique fingerprint.

Cite this